Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung CancerBusiness Wire • 01/04/22
Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatmentMarket Watch • 01/03/22
8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVEInvestorPlace • 01/03/22
Genprex targets non-small cell lung cancer and diabetes via gene therapyProactive Investors • 01/03/22
Genprex wins Fast Track designation for REQORSA in combo with Keytruda for treating Non-Small Cell Lung Cancer from FDAProactive Investors • 01/03/22
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer SettingBenzinga • 01/03/22
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 01/03/22
Genprex strengthens leadership team with appointments to newly-created positions of chief medical officer and of chief manufacturing and technology officerProactive Investors • 09/28/21
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D.Business Wire • 09/28/21
Genprex gears up for patient enrollment in its Acclaim-1 REQORSA trial after FDA feedbackProactive Investors • 06/23/21
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA ReviewBusiness Wire • 06/23/21
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancerProactive Investors • 05/06/21
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung CancerBusiness Wire • 05/06/21
Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung cancerProactive Investors • 05/05/21
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung CancerBusiness Wire • 05/05/21
Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSAProactive Investors • 05/04/21